Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment‐naïve (AMBER) and virologically suppressed (EMERALD) participants with neurological and/or psychiatric comorbidities: Week 96 subgroup analysis

Objective Our objective was to evaluate the prevalence of pre‐existing neurological and/or psychiatric comorbidities (NPCs) and efficacy/safety outcomes for participants with versus without baseline NPCs in AMBER and EMERALD. Methods AMBER (treatment‐naïve population) and EMERALD (virologically supp...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	HIV medicine 2023-03, Vol.24 (3), p.279-289
Hauptverfasser:	Dunn, Keith, Bushen, Jennifer, Luo, Donghan, Cai, Jiyun, Simonson, Richard Bruce, Anderson, David
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-HIV Agents - therapeutic use antiretroviral agents Cobicistat - adverse effects Comorbidity darunavir Darunavir - therapeutic use Drug Combinations Emtricitabine Emtricitabine - therapeutic use HIV HIV Infections - drug therapy HIV‐1 Human immunodeficiency virus Humans neurological psychiatric Subgroups Tenofovir
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Objective Our objective was to evaluate the prevalence of pre‐existing neurological and/or psychiatric comorbidities (NPCs) and efficacy/safety outcomes for participants with versus without baseline NPCs in AMBER and EMERALD. Methods AMBER (treatment‐naïve population) and EMERALD (virologically suppressed population) were phase III randomized studies of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg. The primary objective of this post hoc analysis was to assess virological response (HIV‐1 RNA
ISSN:	1464-2662 1468-1293
DOI:	10.1111/hiv.13377